New hope for Hard-to-Treat hepatitis c: Two-Drug combo shows promise in early trial
NCT ID NCT07316842
First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study is following 30 adults with chronic hepatitis C genotype 3 and mild to moderate liver fibrosis (stages F0-F2) who are taking the antiviral drugs ravidasvir and sofosbuvir as part of their regular care. Researchers want to see how many people have no detectable virus in their blood 12 weeks after finishing treatment. The goal is to learn whether this drug combination works well for this specific group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIRAL HEPATITIS C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center of Target Therapy LLC.
Moscow, 125008, Russia
Conditions
Explore the condition pages connected to this study.